NCT04691973Active, not recruiting
Evaluation of Health and Lifestyle Tool
Evaluation of the Digital Health and Lifestyle Tool
Source: ClinicalTrials.gov · Last updated 16 Jul 2025
Brief summary (registry, in English)
The overall aim of the study is to observe the natural pattern of usage and metabolic outcomes in patients with type 2 diabetes who had access to the new digital tool as a stand-alone support in addition to usual care. The tool is based on self-affirmation theory and has large emphasis on self-reflection to enable sustainable lifestyle changes. The changes in HbA1c, reflecting long-term blood glucose, will be evaluated in patients with type 2 diabetes. Patients are compared to controls on usual care not exposed to the tool.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 300 (estimated)
- First submitted
- 30 Dec 2020
- Start date
- 1 Jan 2017
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- Region Skane
- Diseases
- Type 2 diabetes
- NCT number
- NCT04691973
What you commit to
- Study type: Observational
- Planned participants: 300
- From 1 Jan 2017 to the primary completion date, 31 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- type 1 diabetes, MODY or secondary diabetes
- conditions or treatments that in the judgement of the Investigator could affect the study evaluation
Other
- connection with the study team, funders, authorities, universities or other public or private bodies in such a way that specific interests in the study outcomes could be suspected.
Who the study is looking for
- Patients with type 2 diabetes at or above 35 years of age
- HbA1C at 52 mmol/mol or above
- Diagnosis of diabetes mellitus was based on prior documentation or treatment with anti-hyperglycemic medication
- written informed consent.
Age in the registry: 35 years to - · Sex: All
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Clinical Research Center Coordinator of this site? Confirm its status | Malmö | Sweden | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.